Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 17/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580657 | 1.00 | KLKB1 (0.47) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29580618 | 0.94 | KLKB1 (0.54) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL28721899 | 0.94 | KLKB1 (0.54) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL28724191 | 0.92 | KLKB1 (0.46) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29581385 | 0.92 | KLKB1 (0.46) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29638930 | 0.89 | KLKB1 (0.43) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29638927 | 0.89 | KLKB1 (0.43) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29580998 | 0.89 | KLKB1 (0.46) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL28719033 | 0.89 | KLKB1 (0.46) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29581741 | 0.88 | KLKB1 (0.44) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108289893-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-04-12 | — | — | CN | disclosed |